ArticleFrontiers in pediatrics2026
Patient pathways, presentation time, time to diagnosis, and early survival outcomes in pediatric acute lymphoblastic leukemia at Muhimbili National Hospital, Dar es Salaam, Tanzania.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Tanzanian healthcare system is complex, and weaknesses in referral pathways for time-sensitive conditions such as cancer contribute to poor outcomes among pediatric oncology patients. Early presentation and timely diagnosis are essential for improving survival in pediatric leukemia; however, evidence describing delays within Tanzania's referral system and their effects on early survival in children with acute lymphoblastic leukemia (ALL) remains limited. This study addresses this gap by characterizing patient pathways, estimating time to presentation and diagnosis, and assessing early survival among children with ALL treated at Muhimbili National Hospital (MNH). Methods: We conducted a hospital-based retrospective observational cohort study among 64 pediatric patients with a confirmed diagnosis of ALL admitted to the Pediatric Oncology Unit of Muhimbili National Hospital between January and December 2024. Descriptive statistics were used to summarize patient pathways, presentation time, and diagnosis. Six- and twelve-month survival probability was estimated using Kaplan-Meier methods, and survival outcome differences were assessed using the log-rank test. Results: Sixty-four children with ALL were included; more than half (67.2%) were boys, and the median age at diagnosis was 6 years. Nearly half of the children (46.9%) were aged 0-5 years. Most children (51.6%) first sought care at primary-level facilities, whereas only 18.8% were referred from secondary-level facilities. The median time from symptom onset to presentation at MNH was 28.5 days, followed by a median time to diagnosis of 14 days. Six- and 12-month survival probabilities were 79% and 72%, respectively. Survival did not differ significantly by gender (log-rank Conclusion: Overall, delays in presentation and referral remain significant barriers in the management of childhood ALL in this setting. Most mortality occurred during the early treatment period, highlighting the critical importance of strengthening supportive care, early complication management, and infection control alongside improvements in referral systems. Efforts to strengthen early detection and build capacity at lower-level health facilities may substantially improve survival among children with ALL in Tanzania and other low-resource settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.